Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements

2.

Umeda

M

,

Ma

J

,

Westover

T

, et al.

A new genomic framework to categorize pediatric acute myeloid leukemia

.

Nat Genet

.

2024

;

56

(

2

):

281

-

293

.

3.

Fornerod

M

,

Ma

J

,

Noort

S

, et al.

Integrative genomic analysis of pediatric myeloid-related acute leukemias identifies novel subtypes and prognostic indicators

.

Blood Cancer Discov

.

2021

;

2

(

6

):

586

-

599

.

4.

Krizsán

S

,

Péterffy

B

,

Egyed

B

, et al.

Next-generation sequencing-based genomic profiling of children with acute myeloid leukemia

.

J Mol Diagn

.

2023

;

25

(

8

):

555

-

568

.

5.

Tarlock

K

,

Zhong

S

,

He

Y

, et al.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling

.

Oncotarget

.

2018

;

9

(

41

):

26417

-

26430

.

6.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

7.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

8.

Dokal

I

,

Tummala

H

,

Vulliamy

T

.

Inherited bone marrow failure in the pediatric patient

.

Blood

.

2022

;

140

(

6

):

556

-

570

.

9.

Cooper

TM

,

Alonzo

TA

,

Tasian

SK

, et al.

Children's Oncology Group's 2023 blueprint for research: myeloid neoplasms

.

Pediatr Blood Cancer

.

2023

;

70

(

suppl 6

):

e30584

.

10.

Abrahamsson

J

,

Forestier

E

,

Heldrup

J

, et al.

Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate

.

J Clin Oncol

.

2011

;

29

(

3

):

310

-

315

.

11.

Rasche

M

,

Steidel

E

,

Kondryn

D

, et al.

Impact of a risk-adapted treatment approach in pediatric AML: a report of the AML-BFM registry 2012

.

Blood

.

2019

;

134

(

suppl 1

):

293

.

12.

Huang

BJ

,

Meyer

LK

,

Lamble

A

, et al.

Impact of molecular risk on efficacy of blood and marrow transplantation for pediatric acute myeloid leukemia: a report from the Children's Oncology Group

.

Blood

.

2023

;

142

(

suppl 1

):

655

.

13.

de Rooij

JD

,

Masetti

R

,

van den Heuvel-Eibrink

MM

, et al.

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study

.

Blood

.

2016

;

127

(

26

):

3424

-

3430

.

14.

Tarlock

K

,

Gerbing

RB

,

Ries

RE

, et al.

Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia

.

Blood Adv

.

2024

;

8

(

9

):

2094

-

2103

.

15.

Pollard

JA

,

Alonzo

TA

,

Gerbing

R

, et al.

Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group protocol AAML1031

.

J Clin Oncol

.

2022

;

40

(

18

):

2023

-

2035

.

16.

Henley

MJ

,

Koehler

AN

.

Advances in targeting ‘undruggable’ transcription factors with small molecules

.

Nat Rev Drug Discov

.

2021

;

20

(

9

):

669

-

688

.

17.

Illendula

A

,

Pulikkan

JA

,

Zong

H

, et al.

Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice

.

Science

.

2015

;

347

(

6223

):

779

-

784

.

18.

Krivtsov

AV

,

Armstrong

SA

.

MLL translocations, histone modifications and leukaemia stem-cell development

.

Nat Rev Cancer

.

2007

;

7

(

11

):

823

-

833

.

19.

Meyer

C

,

Larghero

P

,

Almeida Lopes

B

, et al.

The KMT2A recombinome of acute leukemias in 2023

.

Leukemia

.

2023

;

37

(

5

):

988

-

1005

.

20.

Balgobind

BV

,

Raimondi

SC

,

Harbott

J

, et al.

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

.

Blood

.

2009

;

114

(

12

):

2489

-

2496

.

21.

van Weelderen

RE

,

Harrison

CJ

,

Klein

K

, et al.

Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

.

Blood Adv

.

2024

;

8

(

12

):

3200

-

3213

.

22.

Bertrums

EJM

,

Smith

JL

,

Harmon

L

, et al.

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia

.

Haematologica

.

2023

;

108

(

8

):

2044

-

2058

.

23.

de Rooij

JD

,

Branstetter

C

,

Ma

J

, et al.

Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes

.

Nat Genet

.

2017

;

49

(

3

):

451

-

456

.

24.

August

KJ

,

Aplenc

R

,

Sung

L

, et al.

Adolescents and young adults (AYA) with acute myeloid leukemia (AML) have increased treatment-related mortality with similar outcomes -- a report from the Children's Oncology Group trials AAML03P1 and AAML0531

.

Blood

.

2014

;

124

(

21

):

3672

.

25.

Kaburagi

T

,

Yamato

G

,

Shiba

N

, et al.

Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia

.

Haematologica

.

2022

;

107

(

3

):

583

-

592

.

26.

Lu

KH-N

,

Hoffmeister

L

,

Orhan

E

, et al.

RAS pathway alterations in pediatric AML patients

.

Blood

.

2022

;

140

(

suppl 1

):

6110

-

6111

.

27.

Pollard

JA

,

Guest

E

,

Alonzo

TA

, et al.

Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group trial AAML0531

.

J Clin Oncol

.

2021

;

39

(

28

):

3149

-

3160

.

28.

van Weelderen

RE

,

Klein

K

,

Harrison

CJ

, et al.

Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster Study Group

.

J Clin Oncol

.

2023

;

41

(

16

):

2963

-

2974

.

29.

Gibson

B

,

Baruchel

A

,

Moore

A

, et al.

Favourable outcomes in newly diagnosed paediatric AML with gemtuzumab ozogamicin and risk-stratified therapy: results from the international Phase III Myechild 01 trial

.

Blood

.

2024

;

144

(

suppl 1

):

968

.

30.

Zwaan

CM

,

Reinhardt

D

,

Zimmerman

M

, et al.

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

.

Br J Haematol

.

2010

;

148

(

5

):

768

-

776

.

31.

Gamis

AS

,

Alonzo

TA

,

Meshinchi

S

, et al.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized Phase III Children's Oncology Group trial AAML0531

.

J Clin Oncol

.

2014

;

32

(

27

):

3021

-

3032

.

32.

Wijnen

NE

,

Koedijk

JB

,

Klein

K

, et al.

Treating CD33-positive de novo acute myeloid leukemia in pediatric patients: focus on the clinical value of gemtuzumab ozogamicin

.

Onco Targets Ther

.

2023

;

16

:

297

-

308

.

33.

Ernst

P

,

Fisher

JK

,

Avery

W

,

Wade

S

,

Foy

D

,

Korsmeyer

SJ

.

Definitive hematopoiesis requires the mixed-lineage leukemia gene

.

Dev Cell

.

2004

;

6

(

3

):

437

-

443

.

34.

DiMartino

JF

,

Selleri

L

,

Traver

D

, et al.

The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver

.

Blood

.

2001

;

98

(

3

):

618

-

626

.

35.

Zeisig

BB

,

Milne

T

,

García-Cuéllar

MP

, et al.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization

.

Mol Cell Biol

.

2004

;

24

(

2

):

617

-

628

.

36.

Lacoste

N

,

Utley

RT

,

Hunter

JM

,

Poirier

GG

,

Côte

J

.

Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase

.

J Biol Chem

.

2002

;

277

(

34

):

30421

-

30424

.

37.

Bernt

KM

,

Zhu

N

,

Sinha

AU

, et al.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L

.

Cancer Cell

.

2011

;

20

(

1

):

66

-

78

.

38.

Daigle

SR

,

Olhava

EJ

,

Therkelsen

CA

, et al.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

.

Blood

.

2013

;

122

(

6

):

1017

-

1025

.

39.

Shukla

N

,

Wetmore

C

,

O'Brien

MM

, et al.

Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia

.

Blood

.

2016

;

128

(

22

):

2780

.

40.

Stein

EM

,

Garcia-Manero

G

,

Rizzieri

DA

, et al.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

.

Blood

.

2018

;

131

(

24

):

2661

-

2669

.

41.

Yokoyama

A

,

Somervaille

TC

,

Smith

KS

,

Rozenblatt-Rosen

O

,

Meyerson

M

,

Cleary

ML

.

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis

.

Cell

.

2005

;

123

(

2

):

207

-

218

.

42.

Shi

A

,

Murai

MJ

,

He

S

, et al.

Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia

.

Blood

.

2012

;

120

(

23

):

4461

-

4469

.

43.

Borkin

D

,

He

S

,

Miao

H

, et al.

Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo

.

Cancer Cell

.

2015

;

27

(

4

):

589

-

602

.

44.

Aguilar

A

,

Zheng

K

,

Xu

T

, et al.

Structure-based discovery of M-89 as a highly potent inhibitor of the menin-mixed lineage leukemia (menin-MLL) protein-protein interaction

.

J Med Chem

.

2019

;

62

(

13

):

6015

-

6034

.

45.

Krivtsov

AV

,

Evans

K

,

Gadrey

JY

, et al.

A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia

.

Cancer Cell

.

2019

;

36

(

6

):

660

-

673.e11

.

46.

Eguchi

K

,

Shimizu

T

,

Kato

D

, et al.

Preclinical evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation

.

Blood

.

2021

;

138

(

suppl 1

):

3339

.

47.

Numata

M

,

Haginoya

N

,

Shiroishi

M

, et al.

A novel menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

.

Cancer Cell Int

.

2023

;

23

(

1

):

36

.

48.

Falkenstein

CD

,

Niswander

LM

,

Kessler

L

,

Tomkinson

B

,

Burrows

F

,

Tasian

SK

.

Preclinical in vivo activity of the menin inhibitor ziftomenib (KO-539) in pediatric KMT2A-rearranged acute lymphoblastic leukemia

.

Blood

.

2022

;

140

(

suppl 1

):

3491

-

3492

.

49.

Fiskus

W

,

Daver

N

,

Boettcher

S

, et al.

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

.

Leukemia

.

2022

;

36

(

11

):

2729

-

2733

.

50.

Rausch

J

,

Dzama

MM

,

Dolgikh

N

, et al.

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax

.

Haematologica

.

2023

;

108

(

10

):

2837

-

2843

.

51.

Kwon

MC

,

Thuring

JW

,

Querolle

O

, et al.

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias

.

Blood

.

2024

;

144

(

11

):

1206

-

1220

.

52.

Chen

YX

,

Yan

J

,

Keeshan

K

, et al.

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression

.

Proc Natl Acad Sci U S A

.

2006

;

103

(

4

):

1018

-

1023

.

53.

Yu

BD

,

Hess

JL

,

Horning

SE

,

Brown

GA

,

Korsmeyer

SJ

.

Altered Hox expression and segmental identity in Mll-mutant mice

.

Nature

.

1995

;

378

(

6556

):

505

-

508

.

54.

Mullighan

CG

,

Kennedy

A

,

Zhou

X

, et al.

Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias

.

Leukemia

.

2007

;

21

(

9

):

2000

-

2009

.

55.

Hollink

IH

,

Zwaan

CM

,

Zimmermann

M

, et al.

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

.

Leukemia

.

2009

;

23

(

2

):

262

-

270

.

56.

Noort

S

,

Oosterwijk

Jv

,

Ma

J

, et al.

Analysis of rare driving events in pediatric acute myeloid leukemia

.

Haematologica

.

2023

;

108

(

1

):

48

-

60

.

57.

Kühn

MW

,

Song

E

,

Feng

Z

, et al.

Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia

.

Cancer Discov

.

2016

;

6

(

10

):

1166

-

1181

.

58.

Uckelmann

HJ

,

Kim

SM

,

Wong

EM

, et al.

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

.

Science

.

2020

;

367

(

6477

):

586

-

590

.

59.

Issa

GC

,

Ravandi

F

,

DiNardo

CD

,

Jabbour

E

,

Kantarjian

HM

,

Andreeff

M

.

Therapeutic implications of menin inhibition in acute leukemias

.

Leukemia

.

2021

;

35

(

9

):

2482

-

2495

.

60.

Cuglievan

B

,

Kantarjian

H

,

Rubnitz

JE

, et al.

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community

.

Leukemia

.

2024

;

38

(

10

):

2073

-

2084

.

61.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

62.

Issa

GC

,

Aldoss

I

,

Thirman

MJ

, et al.

Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)

.

J Clin Oncol

.

2025

;

43

(

1

):

75

-

84

.

63.

Zwann MC, Shukla N, Karras N, et al. Pivotal phase 2 results of AUGMENT-101 for revumenib in KMT2Ar acute leukemia: pediatric expereince. 2024 ASPHO conference papers and posters

.

Pediatr Blood Cancer

.

2024

;

71

(

S2

):

e30977

.

64.

Perner

F

,

Stein

EM

,

Wenge

DV

, et al.

MEN1 mutations mediate clinical resistance to menin inhibition

.

Nature

.

2023

;

615

(

7954

):

913

-

919

.

65.

Zhou

X

,

Zhang

L

,

Aryal

S

, et al.

Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia

.

Blood

.

2024

;

144

(

19

):

2018

-

2032

.

66.

Bourgeois

W

,

Cutler

JA

,

Aubrey

BJ

, et al.

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML

.

Blood

.

2024

;

143

(

15

):

1513

-

1527

.

67.

Bourgeois

W

,

Cutler

J

,

Rice

HE

, et al.

Discerning the landscape of Menin inhibitor resistance

.

Blood

.

2024

;

144

(

suppl 1

):

724

.

68.

Shukla N, Guest E

,

Tasian

S K

, et al. Safety and activity of revumenib in combination with fludarabine/cytarabine (FLA) in patients with relapsed/refractory acute leukemias.

Paper presented at: 29th Congress of the European Hematology Association (EHA); 13 June

;

2024; Madrid, Spain

.

69.

Issa

GC

,

Cuglievan

B

,

Daver

N

, et al.

Phase I/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in R/R AML

.

Blood

.

2024

;

144

(

suppl 1

):

216

.

70.

Zeidner

J

,

Lin

Tl

,

Welkie

R

, et al. Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the BEATAML Consortium.

Madrid, Spain

:

Paper presented at: 29th Congress of the European Hematology Association (EHA)

;

13 June 2024

.

71.

Wang

ES

,

Issa

GC

,

Erba

HP

, et al.

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

.

Lancet Oncol

.

2024

;

25

(

10

):

1310

-

1324

.

72.

Zeidan

AM

,

Wang

ES

,

Issa

GC

, et al.

Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007

.

Blood

.

2024

;

144

(

suppl 1

):

214

.

73.

Salzer

E

,

Stutterheim

J

,

Cuglievan

B

, et al.

APAL2020K/ITCC-101: a phase I trial of the Menin inhibitor ziftomenib in combination with chemotherapy in children with relapsed/refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant acute leukemias

.

Blood

.

2024

;

144

(

suppl 1

):

4265.4263

-

4265.4263.4265.3

.

74.

Searle

E

,

Recher

C

,

Abdul-Hay

M

, et al.

Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed/refractory acute leukemia patients with KMT2A and NPM1 alterations

.

Blood

.

2024

;

144

(

suppl 1

):

212

.

75.

Wei

AH

,

Searle

E

,

Aldoss

I

, et al. Phase 1B study of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia with alterations in KMT2A or NPM.

Madrid, Spain

:

Paper presented at: 29th Congress of the European Hematology Association (EHA)

;

13 June 2024

.

76.

Recher

C

,

O'Nions

J

,

Aldoss

I

, et al.

Phase 1b study of Menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations

.

Blood

.

2024

;

144

(

suppl 1

):

215

.

77.

Rasouli

M

,

Troester

S

,

Grebien

F

,

Goemans

BF

,

Zwaan

CM

,

Heidenreich

O

.

NUP98 oncofusions in myeloid malignancies: an update on molecular mechanisms and therapeutic opportunities

.

Hemasphere

.

2024

;

8

(

9

):

e70013

.

78.

Hollink

IHIM

,

van den Heuvel-Eibrink

MM

,

Arentsen-Peters

STCJM

, et al.

NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern

.

Blood

.

2011

;

118

(

13

):

3645

-

3656

.

79.

McNeer

NA

,

Philip

J

,

Geiger

H

, et al.

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia

.

Leukemia

.

2019

;

33

(

8

):

1934

-

1943

.

80.

Radu

A

,

Moore

MS

,

Blobel

G

.

The peptide repeat domain of nucleoporin Nup98 functions as a docking site in transport across the nuclear pore complex

.

Cell

.

1995

;

81

(

2

):

215

-

222

.

81.

Wang

GG

,

Cai

L

,

Pasillas

MP

,

Kamps

MP

.

NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis

.

Nat Cell Biol

.

2007

;

9

(

7

):

804

-

812

.

82.

Gough

SM

,

Slape

CI

,

Aplan

PD

.

NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights

.

Blood

.

2011

;

118

(

24

):

6247

-

6257

.

83.

Terlecki-Zaniewicz

S

,

Humer

T

,

Eder

T

, et al.

Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression

.

Nat Struct Mol Biol

.

2021

;

28

(

2

):

190

-

201

.

84.

Xu

H

,

Valerio

DG

,

Eisold

ME

, et al.

NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis

.

Cancer Cell

.

2016

;

30

(

6

):

863

-

878

.

85.

Kasper

LH

,

Brindle

PK

,

Schnabel

CA

,

Pritchard

CE

,

Cleary

ML

,

van Deursen

JM

.

CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity

.

Mol Cell Biol

.

1999

;

19

(

1

):

764

-

776

.

86.

Yung

E

,

Sekulovic

S

,

Argiropoulos

B

, et al.

Delineating domains and functions of NUP98 contributing to the leukemogenic activity of NUP98-HOX fusions

.

Leuk Res

.

2011

;

35

(

4

):

545

-

550

.

87.

Oka

M

,

Mura

S

,

Yamada

K

, et al.

Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes

.

Elife

.

2016

;

5

:

e09540

.

88.

Takeda

A

,

Sarma

NJ

,

Abdul-Nabi

AM

,

Yaseen

NR

.

Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins

.

J Biol Chem

.

2010

;

285

(

21

):

16248

-

16257

.

89.

Calvo

KR

,

Sykes

DB

,

Pasillas

MP

,

Kamps

MP

.

Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1

.

Oncogene

.

2002

;

21

(

27

):

4247

-

4256

.

90.

Heikamp

EB

,

Henrich

JA

,

Perner

F

, et al.

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML

.

Blood

.

2022

;

139

(

6

):

894

-

906

.

91.

Issa

GC

,

Cuglievan

B

,

DiNardo

CD

, et al.

Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE)

.

Blood

.

2023

;

142

(

suppl 1

):

58

.

92.

Schmoellerl

J

,

Barbosa

IAM

,

Eder

T

, et al.

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

.

Blood

.

2020

;

136

(

4

):

387

-

400

.

93.

Lopez

CK

,

Noguera

E

,

Stavropoulou

V

, et al.

Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia

.

Cancer Discov

.

2019

;

9

(

12

):

1736

-

1753

.

94.

Kivioja

JL

,

Thanasopoulou

A

,

Kumar

A

, et al.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1⁺/FLT3-ITD⁺ acute myeloid leukemia

.

Leukemia

.

2019

;

33

(

6

):

1360

-

1372

.

95.

Gress

V

,

Roussy

M

,

Boulianne

L

, et al.

CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216

.

Blood Adv

.

2024

;

8

(

1

):

112

-

129

.

96.

Smith

SM

,

Lee

A

,

Tong

S

, et al.

Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy

.

Cold Spring Harb Mol Case Stud

.

2022

;

8

(

5

):

a006220

.

97.

Klairmont

MM

,

Choi

JK

.

Mixed-phenotype acute leukemia, T/megakaryoblastic

.

Blood

.

2018

;

132

(

22

):

2418

.

98.

Neault

M

,

Lebert-Ghali

C

,

Fournier

M

, et al.

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax

.

Cell Rep

.

2023

;

42

(

9

):

113084

.

99.

Niswander

LM

,

Chung

P

,

Diorio

C

,

Tasian

SK

.

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax

.

Haematologica

.

2023

;

108

(

11

):

3142

-

3147

.

100.

Mishra

AK

,

Mullanfiroze

K

,

Chiesa

R

,

Vora

A

.

Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia

.

Pediatr Blood Cancer

.

2021

;

68

(

11

):

e29221

.

101.

Eidenschink Brodersen

L

,

Alonzo

TA

,

Menssen

AJ

, et al.

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group

.

Leukemia

.

2016

;

30

(

10

):

2077

-

2080

.

102.

Le

Q

,

Hadland

B

,

Smith

JL

, et al.

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

.

J Clin Invest

.

2022

;

132

(

22

):

e157101

.

103.

Scaranti

M

,

Cojocaru

E

,

Banerjee

S

,

Banerji

U

.

Exploiting the folate receptor α in oncology

.

Nat Rev Clin Oncol

.

2020

;

17

(

6

):

349

-

359

.

104.

Nawaz

FZ

,

Kipreos

ET

.

Emerging roles for folate receptor FOLR1 in signaling and cancer

.

Trends Endocrinol Metab

.

2022

;

33

(

3

):

159

-

174

.

105.

Oaknin

A

,

Fariñas-Madrid

L

,

García-Duran

C

, et al.

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): update of STRO-002-GM1 phase 1 dose expansion cohort

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

5508

.

106.

Tang

T

,

Le

Q

,

Castro

S

, et al.

Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate

.

Blood Adv

.

2022

;

6

(

22

):

5933

-

5937

.

107.

Williams

R

,

Miller

L

,

Massaro

S

, et al.

Anti-leukemic activity of luveltamab tazevibulin (LT, STRO-002), a novel folate receptor-α (FR-α)-targeting antibody drug conjugate (ADC) in relapsed/refractory CBF2AT3::GLIS2 AML

.

Blood

.

2023

;

142

(

suppl 1

):

4295

.

108.

Le

Q

,

Hadland

B

,

Smith

JL

, et al.

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

.

J Clin Invest

.

2024

;

134

(

16

):

e184305

.

109.

Scheidegger

N

,

Alexe

G

,

Khalid

D

, et al.

Combining Menin and MEK inhibition to target poor prognostic KMT2A-rearranged RAS pathway-mutant acute leukemia

.

Blood

.

2023

;

142

(

suppl 1

):

166

.

110.

Ostronoff

F

,

Othus

M

,

Gerbing

RB

, et al.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

.

Blood

.

2014

;

124

(

15

):

2400

-

2407

.

111.

Tarlock

K

,

Alonzo

TA

,

Gerbing

RB

, et al.

Distinct co-occurring mutational profiles in acute myeloid leukemia confers prognostic significance in children and young adults with FLT3/ITD mutations

.

Blood

.

2018

;

132

(

suppl 1

):

443

.

112.

Thanasopoulou

A

,

Tzankov

A

,

Schwaller

J

.

Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction

.

Haematologica

.

2014

;

99

(

9

):

1465

-

1471

.

113.

Struski

S

,

Lagarde

S

,

Bories

P

, et al.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

.

Leukemia

.

2017

;

31

(

3

):

565

-

572

.